The perioperational efficacy of meglumine cyclic adenylate in direct vision cardiac surgery;

Objective: To explore the therapeutic effect of meglumine cyclic adenylate(McAMP) in chronic heart failure(CHF).

Meglumine cyclic adenylate treatment for tachycardiomyopathy after radiofrequency catheter ablation;

Objective To investigate the efficacy and safety of drug compatibility of Isosorbide Dinitrate(ISD), Meglumine cyclic adenylate(MCA)and Potassium Magnesium Aspartate(PMA)in the patients with unstable angina pectoris (UA).

Effect of Xinxianan injection on the lung and heart function in chronic Cor Pulmonale patients;

Myocardial protection of Megluming cyclic adenylate on myocardial ischemic and reperfusion injury in patients undergoing valve replacement during cardiopulmonary bypass;

Objective To investigate the myocardial protection of megluming cyclic adenylate(M-cAMP) during non-cardiac surgery in the patients with coronary artery disease.

Methods A total of 89 patients were divided into two groups randomly:the control group (44 cases) received the routine treatment and the treated group (45 cases) received the routine treatment and intravenous injection of meglumine adenosine cyclophosphate,120 mg every time,once daily.

To explore the effects of meglumine adenosine cyclophosphate(MAC)on heart function in pa- tients with heart failure of ischemic cardidmyopathy(ICM).

Meglumine adenosine cyclophosphate injection(180mg) was added into the prime perfusate during ECC in treated group(n=24),but not in control group(n=24).